689 related articles for article (PubMed ID: 21771874)
1. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
2. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
[TBL] [Abstract][Full Text] [Related]
3. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
de Vries IJ; Bernsen MR; Lesterhuis WJ; Scharenborg NM; Strijk SP; Gerritsen MJ; Ruiter DJ; Figdor CG; Punt CJ; Adema GJ
J Clin Oncol; 2005 Aug; 23(24):5779-87. PubMed ID: 16110035
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
5. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.
Bedrosian I; Mick R; Xu S; Nisenbaum H; Faries M; Zhang P; Cohen PA; Koski G; Czerniecki BJ
J Clin Oncol; 2003 Oct; 21(20):3826-35. PubMed ID: 14551301
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
7. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
9. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
[TBL] [Abstract][Full Text] [Related]
10. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
[TBL] [Abstract][Full Text] [Related]
13. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
14. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.
Schuurhuis DH; Verdijk P; Schreibelt G; Aarntzen EH; Scharenborg N; de Boer A; van de Rakt MW; Kerkhoff M; Gerritsen MJ; Eijckeler F; Bonenkamp JJ; Blokx W; van Krieken JH; Boerman OC; Oyen WJ; Punt CJ; Figdor CG; Adema GJ; de Vries IJ
Cancer Res; 2009 Apr; 69(7):2927-34. PubMed ID: 19318559
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
Bol KF; Aarntzen EH; Pots JM; Olde Nordkamp MA; van de Rakt MW; Scharenborg NM; de Boer AJ; van Oorschot TG; Croockewit SA; Blokx WA; Oyen WJ; Boerman OC; Mus RD; van Rossum MM; van der Graaf CA; Punt CJ; Adema GJ; Figdor CG; de Vries IJ; Schreibelt G
Cancer Immunol Immunother; 2016 Mar; 65(3):327-39. PubMed ID: 26861670
[TBL] [Abstract][Full Text] [Related]
17. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.
Aarntzen EH; Srinivas M; Bonetto F; Cruz LJ; Verdijk P; Schreibelt G; van de Rakt M; Lesterhuis WJ; van Riel M; Punt CJ; Adema GJ; Heerschap A; Figdor CG; Oyen WJ; de Vries IJ
Clin Cancer Res; 2013 Mar; 19(6):1525-33. PubMed ID: 23382117
[TBL] [Abstract][Full Text] [Related]
18. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
19. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]